Asymptomatic Inflammatory Bowel Disease Diagnosed During Colorectal Cancer Population Screening in Catalonia: Characteristics and Natural History.

IF 3 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Clinical and Translational Gastroenterology Pub Date : 2024-12-26 DOI:10.14309/ctg.0000000000000740

Eduard Brunet-Mas, Anna Selva, Francesc Bas-Cutrina, Anna Brujats, Berta Caballol, Rebeca Font, Bàrbara Gómez, Carlos Gonzalez-Muñosa, David Busquets, David Monfort, Diana Patrícia Vera, Elisabet Maristany, Gemma Cirera, Gisela Torres, Jesús Castro-Poceiro, Joel Lopez, Laura Gonzalez-Gonzalez, Lucia Màrquez-Mosquera, Marta Gallach, Maria Esteve, Gemma Tremosa, Sandra Torra, Virginia Robles-Alonso, Pilar Garcia-Iglesias, Iago Rodríguez-Lago, Xavier Calvet

{"title":"Asymptomatic Inflammatory Bowel Disease Diagnosed During Colorectal Cancer Population Screening in Catalonia: Characteristics and Natural History.","authors":"Eduard Brunet-Mas, Anna Selva, Francesc Bas-Cutrina, Anna Brujats, Berta Caballol, Rebeca Font, Bàrbara Gómez, Carlos Gonzalez-Muñosa, David Busquets, David Monfort, Diana Patrícia Vera, Elisabet Maristany, Gemma Cirera, Gisela Torres, Jesús Castro-Poceiro, Joel Lopez, Laura Gonzalez-Gonzalez, Lucia Màrquez-Mosquera, Marta Gallach, Maria Esteve, Gemma Tremosa, Sandra Torra, Virginia Robles-Alonso, Pilar Garcia-Iglesias, Iago Rodríguez-Lago, Xavier Calvet","doi":"10.14309/ctg.0000000000000740","DOIUrl":null,"url":null,"abstract":"Introduction: Inflammatory bowel disease (IBD) is usually diagnosed when symptomatic. Prognosis and evolution of preclinical IBD is largely unknown. However, colorectal cancer screening programs (CRCSP) detect a subset of patients with IBD with no symptoms. The aim of this study was to describe the natural history of asymptomatic IBD diagnosed through CRCSP.Methods: An observational, longitudinal, and retrospective study was performed at 22 centers in Catalonia between January 2010 and December 2019 including patients with asymptomatic IBD detected in the CRCSP. Demographic data and IBD characteristics, evolution, and treatment were recorded. Descriptive statistics and Kaplan-Meier analysis were used for the analysis. Data were given separately for IBD, Crohn's disease (CD), ulcerative colitis (UC), and IBD unclassified (IBDU).Results: One hundred eighty-eight patients were included: 103 UC (54.8%), 60 CD (31.9%), and 25 IBDU (13.3%). Sixty-six (35.1%) were women, and the average age was 59.9 ± 5.9 years. Sixty-four patients (34.0%) developed symptoms after a median follow-up of 35.6 months. Diarrhea was the most frequent symptom for CD and IBDU (25.4% and 11.5%, respectively) and blood in stools for UC (21.4%). The median time to first symptom was 11.6 months. Treatment was prescribed in 135 patients (72.2%); mesalazine was the most prescribed drug (123 patients; 65.4%). Thirteen patients (6.9%) required biological treatment. None underwent surgery.Discussion: Around one-third of asymptomatic patients with IBD developed symptoms after a medium follow-up of 3 years. Only 6.9% required biological treatment, and none required surgery. Overall, prognosis of asymptomatic IBD seems better.","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14309/ctg.0000000000000740","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Inflammatory bowel disease (IBD) is usually diagnosed when symptomatic. Prognosis and evolution of preclinical IBD is largely unknown. However, colorectal cancer screening programs (CRCSP) detect a subset of patients with IBD with no symptoms. The aim of this study was to describe the natural history of asymptomatic IBD diagnosed through CRCSP.

Methods: An observational, longitudinal, and retrospective study was performed at 22 centers in Catalonia between January 2010 and December 2019 including patients with asymptomatic IBD detected in the CRCSP. Demographic data and IBD characteristics, evolution, and treatment were recorded. Descriptive statistics and Kaplan-Meier analysis were used for the analysis. Data were given separately for IBD, Crohn's disease (CD), ulcerative colitis (UC), and IBD unclassified (IBDU).

Results: One hundred eighty-eight patients were included: 103 UC (54.8%), 60 CD (31.9%), and 25 IBDU (13.3%). Sixty-six (35.1%) were women, and the average age was 59.9 ± 5.9 years. Sixty-four patients (34.0%) developed symptoms after a median follow-up of 35.6 months. Diarrhea was the most frequent symptom for CD and IBDU (25.4% and 11.5%, respectively) and blood in stools for UC (21.4%). The median time to first symptom was 11.6 months. Treatment was prescribed in 135 patients (72.2%); mesalazine was the most prescribed drug (123 patients; 65.4%). Thirteen patients (6.9%) required biological treatment. None underwent surgery.

Discussion: Around one-third of asymptomatic patients with IBD developed symptoms after a medium follow-up of 3 years. Only 6.9% required biological treatment, and none required surgery. Overall, prognosis of asymptomatic IBD seems better.

查看原文本刊更多论文

加泰罗尼亚结直肠癌人群筛查中诊断的无症状炎性肠病：特征和自然史

简介：炎症性肠病（IBD）通常在出现症状时被诊断出来。临床前IBD的预后和发展在很大程度上是未知的。然而，结直肠癌筛查项目（CRCSP）检测到一部分没有症状的IBD患者。本研究的目的是描述通过CRCSP诊断的无症状IBD的自然史。方法：2010年1月至2019年12月，在加泰罗尼亚的22个中心进行了一项观察性、纵向和回顾性研究，包括在CRCSP中检测到的无症状IBD患者。记录人口统计学数据和IBD的特征、演变和治疗。采用描述性统计和Kaplan-Meier分析。分别给出了IBD、克罗恩病（CD）、溃疡性结肠炎（UC）和IBD未分类（IBDU）的数据。结果：共纳入188例患者：UC 103例（54.8%），CD 60例（31.9%），IBDU 25例（13.3%）。女性66例（35.1%），平均年龄59.9±5.9岁。64例患者（34.0%）在中位随访35.6个月后出现症状。腹泻是乳糜泻和IBDU最常见的症状（分别为25.4%和11.5%），UC最常见的症状是便血（21.4%）。至首次出现症状的中位时间为11.6个月。135例患者（72.2%）接受了治疗；美沙拉嗪是处方最多的药物（123例）；65.4%)。13例（6.9%）患者需要生物治疗。没有人接受手术。结论：大约三分之一的无症状IBD患者在3年的中等随访后出现症状。只有6.9%需要生物治疗，没有人需要手术治疗。总体而言，无症状IBD预后较好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Translational Gastroenterology GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

7.00

自引率

0.00%

发文量

114

审稿时长

16 weeks

期刊介绍： Clinical and Translational Gastroenterology (CTG), published on behalf of the American College of Gastroenterology (ACG), is a peer-reviewed open access online journal dedicated to innovative clinical work in the field of gastroenterology and hepatology. CTG hopes to fulfill an unmet need for clinicians and scientists by welcoming novel cohort studies, early-phase clinical trials, qualitative and quantitative epidemiologic research, hypothesis-generating research, studies of novel mechanisms and methodologies including public health interventions, and integration of approaches across organs and disciplines. CTG also welcomes hypothesis-generating small studies, methods papers, and translational research with clear applications to human physiology or disease. Colon and small bowel Endoscopy and novel diagnostics Esophagus Functional GI disorders Immunology of the GI tract Microbiology of the GI tract Inflammatory bowel disease Pancreas and biliary tract Liver Pathology Pediatrics Preventative medicine Nutrition/obesity Stomach.